These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35766967)

  • 1. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
    Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
    Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
    Wu D; Li Y; Xu P; Fang Q; Cao F; Lin H; Li Y; Su Y; Lu L; Chen L; Li Y; Zhao Z; Hong X; Li G; Tian Y; Sun J; Yan H; Fan Y; Zhang X; Li Z; Liu X
    Nat Commun; 2024 Mar; 15(1):2177. PubMed ID: 38467604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
    Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
    J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
    Huang Y; Sun J; Li J; Zhu D; Dong M; Dou S; Tang Y; Shi W; Sun Q; Zhao T; Zhou Z; Zhou X; Liu Y; Li J; Zhu G; Zhang D; Chen Y; Zhu Q; Ju W; Zhong L
    Int J Surg; 2023 Aug; 109(8):2220-2227. PubMed ID: 37288582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
    Qin J; Xue L; Hao A; Guo X; Jiang T; Ni Y; Liu S; Chen Y; Jiang H; Zhang C; Kang M; Lin J; Li H; Li C; Tian H; Li L; Fu J; Zhang Y; Ma J; Wang X; Fu M; Yang H; Yang Z; Han Y; Chen L; Tan L; Dai T; Liao Y; Zhang W; Li B; Chen Q; Guo S; Qi Y; Wei L; Li Z; Tian Z; Kang X; Zhang R; Li Y; Wang Z; Chen X; Hou Z; Zheng R; Zhu W; He J; Li Y
    Nat Med; 2024 Sep; 30(9):2549-2557. PubMed ID: 38956195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.
    Wang K; Gui L; Lu H; He X; Li D; Liu C; Liu S; Wang X
    Front Immunol; 2023; 14():1189752. PubMed ID: 37583698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
    Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
    Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study.
    Sheng Y; Meng X; Zhang C; Shan Z; Li F; Wu B; Xu M; Li A; Guan L; Chen L; Sun S; Ma Y; Lu T; Zhao S; Fan Q; Qi Y; Wang F
    J Thorac Dis; 2024 Aug; 16(8):5337-5347. PubMed ID: 39268120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Zhao X; Zhou Y; Peng G; Wen L; Hong X; Hu Y; Wu B; Liu X; Zhang Z; Xiao G; JingHuang ; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Wei J; Qin Y; Wan C; Zhong Y; Leng Y; Zhang T; Wu G; MinYao ; Jia Y; Zhang X; Yang K
    Oral Oncol; 2024 Sep; 156():106918. PubMed ID: 38943870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Tanaka R; Ueki Y; Ohshima S; Omata J; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Togashi T; Horii A
    Int J Clin Oncol; 2024 Aug; 29(8):1133-1141. PubMed ID: 38727853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of induction chemoimmunotherapy for locally advanced hypopharyngeal carcinoma: a prospective phase Ⅱ study].
    Gong HL; Tian S; Ding H; Tao L; Wang L; Wang J; Wang T; Zhang M; Shi Y; Xu CZ; Wu CP; Wang SZ; Zhou L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):350-356. PubMed ID: 38599645
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
    Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
    Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
    Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study.
    Wu WJ; Liu Q; An PG; Wang L; Zhang JY; Chen Y; Zhang T; Zhang J
    Front Immunol; 2023; 14():1282629. PubMed ID: 38035079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
    Wang J; Zhang J; Gao J; Zhao M; Ma Z
    Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.